Spectrum Regenerative

Spectrum Regenerative (also known as HZ4 Liver Inc.) is an American preclinical biotechnology company focused on developing precision regenerative medicines to treat advanced liver diseases. Founded in 2022 by venture studio Securitas Biosciences, the company targets master molecular regulators of tissue damage, repair, and regeneration using a modality-agnostic approach that includes small molecules, siRNA, and antibodies. Its lead candidate, HZ01, is a small molecule designed to promote liver regeneration, reduce oxidative stress, and inhibit tumor growth, showing promising results in preclinical models of liver injury and hepatocellular carcinoma. Additionally, Spectrum Regenerative is developing an ex vivo platform designed to rescue marginal donor organs and grow partial livers to transplantable size, aiming to expand the donor organ pool and keep patients off transplant lists.